Abingdon Health plc
("Abingdon Health" or "the Company")
Notice of results
Investor presentation
York, U.K. 17 March 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, will announce its unaudited interim results for the six months ended 31 December 2024 on Monday 24 March 2025.
Investor Presentation
The Company will provide a live presentation relating to the preliminary results via the Investor Meet Company platform on Wednesday 26 March at 11:00 GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Abingdon Health plc via:
https://www.investormeetcompany.com/abingdon-health-plc/register-investor
Investors who already follow Abingdon Health plc on the Investor Meet Company platform will automatically be invited.
Enquiries
| Abingdon Health plc | ||
| Chris Yates, Chief Executive Officer | Via Walbrook PR | |
| Chris Hand, Executive Chairman
| | |
| Zeus Capital (Sole Broker and Nominated Adviser) | Tel: +44 (0) 20 3829 5000 | |
| Antonio Bossi / Alexandra Campbell-Harris (Corporate Finance) | | |
| Fraser Marshall (Corporate Broking) | | |
| | | |
| Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
| Phillip Marriage | +44 (0)7867 984 082 | |
About Abingdon Health plc
Abingdon Health is a leading med-tech contract service provider offering its services to an international customer base.
The Group's CDMO division offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internally (e.g. Quality Management Systems) and externally (e.g. critical suppliers), management reviews and presentations, training and mentoring.
Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range and other selected self-test products, such as the saliva pregnancy test, SalistickTM, is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York, England with CDMO facilities in both York, UK and Madison, Wisconsin, USA. For more information visit: www.abingdonhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
